Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Urigen

Criteria

Inclusion Criteria:

• male and female subjects >= 18 years of age

• moderate to severe symptoms of PBS/IC

• minimum pain/urgency/frequency scores

• female subjects on hormone therapy must be on stable dose for >= 3 months

Exclusion Criteria:

• positive pregnancy test or pregnant or lactating

• narcotics or medical marijuana within 3 months

• use of any investigational drug or device within 30 days

• bacterial cystitis within 30 days